OpenMed-NER-OncologyDetect-MultiMed-335M

모델 소개

This model is a **state-of-the-art** fine-tuned transformer engineered to deliver **enterprise-grade accuracy** for cancer genetics - cancer-related genetic entities. This specialized model excels at identifying and extracting biomedical entities from clinical texts, research papers, and healthcare documents, enabling applications such as **drug interaction detection**, **medication extraction from patient records**, **adverse event monitoring**, **literature mining for drug discovery**, and **biomedical knowledge graph construction** with **production-ready reliability** for clinical and research applications. The BioNLP 2013 CG (Cancer Genetics) corpus is a specialized dataset focusing on cancer genetics entities and gene regulation in oncology research. This corpus contains annotations for genes, proteins, and molecular processes specifically related to cancer biology and tumor genetics. Developed for the BioNLP Shared Task 2013, it supports the development of text mining systems for cancer research, oncological studies, and precision medicine applications. The dataset is particularly valuable for identifying cancer-related biomarkers, tumor suppressor genes, oncogenes, and therapeutic targets mentioned in cancer research literature. It serves as a benchmark for evaluating NER systems used in cancer genomics, personalized medicine, and oncology informatics. *Figure: OpenMed (Open-Source) vs. Latest SOTA (Closed-Source) performance comparison across biomedical NER datasets.*

주요 특징

特点摘要待依据来源补齐，不凭模型名称推断能力。

한계 및 유의 사항

구체적 한계를 판단할 출처가 부족합니다. 실제 성능, 지연, 데이터 정책, 라이선스와 버전 수명을 확인하세요.

출처별 요금 및 비용 분석

요금은 채널, 지역, 설정에 따라 다릅니다. 각 채널 요금은 개별 표시되며 제공사의 통일 공식 요금이 아닙니다.

공개 평가 및 실행 설정

暂无已采集的可核验公开评分。模型未上榜不代表能力较低。

자주 묻는 질문

출처 및 추적 기록

许可证：apache-2.0。模型介绍与第三方评测均以原来源的具体版本和方法为准。